Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55,705,828
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
20,241,451
-
Shares change
-
+454,326
-
Total reported value, excl. options
-
$176,086,818
-
Value change
-
+$3,320,960
-
Put/Call ratio
-
0%
-
Number of buys
-
39
-
Number of sells
-
-29
-
Price
-
$8.70
Significant Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q1 2022
108 filings reported holding SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2022.
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20,241,451 shares
of 55,705,828 outstanding shares and own 36% of the company stock.
Largest 10 shareholders include Aquilo Capital Management, LLC (5,281,504 shares), BlackRock Inc. (1,794,081 shares), BVF INC/IL (1,585,615 shares), Atlas Venture Associates IX, LLC (1,376,968 shares), VANGUARD GROUP INC (1,373,928 shares), Atlas Venture Life Science Advisors, LLC (1,031,160 shares), Rock Springs Capital Management LP (990,913 shares), Alphabet Inc. (889,979 shares), AMERIPRISE FINANCIAL INC (586,642 shares), and Artal Group S.A. (500,000 shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.